Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:36:43.216Z.
Calculation as of: 2026-10-06T20:36:43.216Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26a6c2e450689c32f4e4e5954cf906f309ed45562a8b136dc87c806878a45fac
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$5.87B
Price/OCF Ratio
31.72
TTM Avg
31.51
3Y Avg
57.31
5Y Avg
58.06
Market Cap
$5.95B
Price/OCF Ratio
45.21
TTM Avg
80.09
3Y Avg
48.34
5Y Avg
34.61
Market Cap
$5.79B
Price/OCF Ratio
N/A
TTM Avg
1.10
3Y Avg
1.10
5Y Avg
1.10
Market Cap
$6.23B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.52B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRAIL Inc. (GRAL) | $5.89B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 31.72 | 31.51 | 57.31 | 58.06 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 45.21 | 80.09 | 48.34 | 34.61 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | N/A | 1.10 | 1.10 | 1.10 |
| Kodiak Sciences Inc. (KOD)vs › | $5.78B | N/A | N/A | N/A | N/A |
| CG Oncology Inc. (CGON)vs › | $5.61B | N/A | N/A | N/A | N/A |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.23B | N/A | N/A | N/A | N/A |
| RadNet, Inc. (RDNT)vs › | $5.53B | 17.43 | 17.73 | 17.23 | 13.87 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | N/A | N/A | N/A | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | N/A | 7.44 | 7.44 | 7.44 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
